{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T16:06:49Z","timestamp":1768406809324,"version":"3.49.0"},"reference-count":122,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.urolonc.2024.12.263","type":"journal-article","created":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T03:34:33Z","timestamp":1736048073000},"page":"401-411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development of point-of-care tests for urinary bladder cancer \u2013 an historic review and view to future prospectives"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0787-2763","authenticated-orcid":false,"given":"Thorsten H.","family":"Ecke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Styrke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiran","family":"Jagarlamudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stig","family":"Linder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.urolonc.2024.12.263_bib0001","doi-asserted-by":"crossref","first-page":"623","DOI":"10.7326\/0003-4819-115-8-623","article-title":"Clinical applications of serum tumor markers","volume":"115","author":"Bates","year":"1991","journal-title":"Ann Inter Med"},{"issue":"4","key":"10.1016\/j.urolonc.2024.12.263_bib0002","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.5301\/jbm.5000251","article-title":"Circulating tumor markers: a guide to their appropriate clinical use comparative summary of recommendations from clinical practice guidelines (PART 1)","volume":"31","author":"Gion","year":"2016","journal-title":"Int J Biol Markers"},{"issue":"2","key":"10.1016\/j.urolonc.2024.12.263_bib0003","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.5301\/ijbm.5000272","article-title":"Circulating tumor markers: a guide to their appropriate clinical use comparative summary of recommendations from clinical practice guidelines (PART 3)","volume":"32","author":"Gion","year":"2017","journal-title":"Int J Biol Markers"},{"issue":"1","key":"10.1016\/j.urolonc.2024.12.263_bib0004","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.5301\/ijbm.5000259","article-title":"Circulating tumor markers: a guide to their appropriate clinical use comparative summary of recommendations from clinical practice guidelines (PART 2)","volume":"32","author":"Gion","year":"2017","journal-title":"Int J Biol Markers"},{"issue":"4","key":"10.1016\/j.urolonc.2024.12.263_bib0005","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1172\/JCI100974","article-title":"An \" Acid \" phosphatase occurring in the serum of patients with metastasizing carcinoma of the prostate gland","volume":"17","author":"Gutman","year":"1938","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.urolonc.2024.12.263_bib0006","first-page":"513","article-title":"Elevation of a serum component in neoplastic disease","volume":"14","author":"Hill","year":"1954","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2024.12.263_bib0007","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000228374","article-title":"Antigenicity of pooled human malignant and normal tissues by cyto-immunological technique: presence of an insoluble, heat-labile tumor antigen","volume":"10","author":"Bj\u00f6rklund","year":"1957","journal-title":"Int Arch Allergy"},{"issue":"2","key":"10.1016\/j.urolonc.2024.12.263_bib0008","first-page":"159","article-title":"Purification of a human prostate specific antigen","volume":"17","author":"Wang","year":"1979","journal-title":"Invest Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2024.12.263_bib0009","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.eururo.2021.07.024","article-title":"Prostate-specific antigen testing as part of a risk-adapted early detection strategy for Prostate cancer: European Association of Urology Position and Recommendations for 2021","volume":"80","author":"Van Poppel","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.12.263_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2023.12.005","article-title":"Comparing the performance of digital rectal examination and prostate-specific antigen as a screening test for prostate cancer: A systematic review and meta-analysis","author":"Matsukawa","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2024.12.263_bib0011","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/jnci\/djp001","article-title":"Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context","volume":"101","author":"Draisma","year":"2009","journal-title":"J Natl Cancer Institute"},{"issue":"16","key":"10.1016\/j.urolonc.2024.12.263_bib0012","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/S1470-2045(15)00361-7","article-title":"Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study","volume":"16","author":"Gronberg","year":"2015","journal-title":"Lancet Oncol"},{"issue":"23-24","key":"10.1016\/j.urolonc.2024.12.263_bib0013","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.cca.2010.08.039","article-title":"CA 15-3: uses and limitation as a biomarker for breast cancer","volume":"411","author":"Duffy","year":"2010","journal-title":"Clin Chim Acta"},{"issue":"3","key":"10.1016\/j.urolonc.2024.12.263_bib0014","first-page":"315","article-title":"Ovarian cancer screening","volume":"25","author":"Rosenthal","year":"1998","journal-title":"Semin Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2024.12.263_bib0015","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1471-0528.2000.tb11685.x","article-title":"Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening","volume":"107","author":"Menon","year":"2000","journal-title":"BJOG"},{"issue":"4","key":"10.1016\/j.urolonc.2024.12.263_bib0016","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000107582","article-title":"Cytokeratin markers come of age","volume":"28","author":"Linder","year":"2007","journal-title":"Tumour Biol"},{"issue":"5","key":"10.1016\/j.urolonc.2024.12.263_bib0017","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/oncolo\/oyac047","article-title":"Circulating biomarkers for therapeutic monitoring of anti-cancer agents","volume":"27","author":"Janse van Rensburg","year":"2022","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.urolonc.2024.12.263_bib0018","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s13277-011-0275-1","article-title":"Utility of serum tumor markers as an aid in the differential diagnosis of patients with clinical suspicion of cancer and in patients with cancer of unknown primary site","volume":"33","author":"Molina","year":"2012","journal-title":"Tumour Biol"},{"issue":"12","key":"10.1016\/j.urolonc.2024.12.263_bib0019","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/s41416-020-0829-3","article-title":"The association between unexpected weight loss and cancer diagnosis in primary care: a matched cohort analysis of 65,000 presentations","volume":"122","author":"Nicholson","year":"2020","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.urolonc.2024.12.263_bib0020","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.21873\/invivo.12634","article-title":"Tumour markers in the differential diagnosis of patients with isolated involuntary weight loss","volume":"35","author":"Trape","year":"2021","journal-title":"In Vivo"},{"issue":"1","key":"10.1016\/j.urolonc.2024.12.263_bib0021","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1186\/s12885-024-12201-0","article-title":"Relevance of blood tumor markers in inpatients with significant involuntary weight loss and elevated levels of inflammation biomarkers","volume":"24","author":"Gronnier","year":"2024","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.urolonc.2024.12.263_bib0022","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA: Cancer J Clin"},{"issue":"19","key":"10.1016\/j.urolonc.2024.12.263_bib0023","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder Cancer: A review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.urolonc.2024.12.263_bib0024","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2011.1142","article-title":"Association between smoking and risk of bladder cancer among men and women","volume":"306","author":"Freedman","year":"2011","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.urolonc.2024.12.263_bib0025","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cncr.28397","article-title":"Trends in stage-specific incidence rates for urothelial carcinoma of the bladder in the United States: 1988 to 2006","volume":"120","author":"Nielsen","year":"2014","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.urolonc.2024.12.263_bib0026","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2024.12.263_bib0027","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/bju.14045","article-title":"Bladder cancer: diagnosis and management of bladder cancer: (c) NICE (2015) Bladder cancer: diagnosis and management of bladder cancer","volume":"120","year":"2017","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.urolonc.2024.12.263_bib0028","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2015.05.050","volume":"69","author":"Sylvester","year":"2016","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.12.263_bib0029","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance Bacillus Calmette-Guerin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.urolonc.2024.12.263_bib0030","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1586\/14737140.7.8.1105","article-title":"Potential of urinary biomarkers in early bladder cancer diagnosis","volume":"7","author":"Lam","year":"2007","journal-title":"Expert Rev Anticancer Therapy"},{"issue":"3","key":"10.1016\/j.urolonc.2024.12.263_bib0031","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000087792","article-title":"Non-invasive diagnostic tests for bladder cancer: a review of the literature","volume":"75","author":"Bassi","year":"2005","journal-title":"Urol Int"},{"issue":"1","key":"10.1016\/j.urolonc.2024.12.263_bib0032","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0094-0143(05)70231-7","article-title":"Urine cytology. It is still the gold standard for screening?","volume":"27","author":"Brown","year":"2000","journal-title":"Urol Clin North Am"},{"issue":"1","key":"10.1016\/j.urolonc.2024.12.263_bib0033","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1017\/S0266462310001364","article-title":"Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: systematic review and meta-analysis","volume":"27","author":"Mowatt","year":"2011","journal-title":"Int J Technol Assess Health Care"},{"issue":"5","key":"10.1016\/j.urolonc.2024.12.263_bib0034","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/S0022-5347(01)64827-4","article-title":"Diagnostic accuracy of urinary cytology, and deoxyribonucleic acid flow cytometry and cytology on bladder washings during followup for bladder tumors","volume":"157","author":"Gregoire","year":"1997","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2024.12.263_bib0035","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1046\/j.1464-4096.2001.01899.x","article-title":"The community-based morbidity of flexible cystoscopy","volume":"89","author":"Burke","year":"2002","journal-title":"BJU International"},{"key":"10.1016\/j.urolonc.2024.12.263_bib0036","article-title":"Urinary markers for bladder cancer diagnosis: A review of current status and future challenges","author":"Tomiyama","year":"2023","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2024.12.263_bib0037","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/978-1-0716-3346-5_11","article-title":"Cell-free DNA, MicroRNAs, proteins, and peptides as liquid biopsy biomarkers in prostate cancer and bladder cancer","volume":"2695","author":"Chen","year":"2023","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.urolonc.2024.12.263_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115027","article-title":"Liquid biopsy in urothelial carcinoma: detection techniques and clinical applications","volume":"165","author":"Wu","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"10.1016\/j.urolonc.2024.12.263_bib0039","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076757","article-title":"Extracellular vesicles as potential bladder cancer biomarkers: take it or leave it?","volume":"24","author":"Teixeira-Marques","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.urolonc.2024.12.263_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ab.2023.115074","article-title":"Proteomics strategies for urothelial bladder cancer diagnosis, prognosis and treatment: trends for tumor biomarker sources","volume":"666","author":"Tabaei","year":"2023","journal-title":"Analyt Biochem"},{"issue":"1","key":"10.1016\/j.urolonc.2024.12.263_bib0041","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ucl.2022.09.009","article-title":"Urine-based markers for detection of urothelial cancer and for the management of non-muscle-invasive bladder cancer","volume":"50","author":"Lotan","year":"2023","journal-title":"Urol Clin North Am"},{"issue":"6","key":"10.1016\/j.urolonc.2024.12.263_bib0042","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.21037\/tau.2017.11.29","article-title":"The contemporary role and impact of urine-based biomarkers in bladder cancer","volume":"6","author":"Duquesne","year":"2017","journal-title":"Transl Androl Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2024.12.263_bib0043","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16040753","article-title":"Urine-based biomarker test uromonitor(R) in the detection and disease monitoring of non-muscle-invasive bladder cancer-A systematic review and meta-analysis of diagnostic test performance","volume":"16","author":"Kravchuk","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.urolonc.2024.12.263_bib0044","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1186\/s12885-016-2748-5","article-title":"Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive\/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer","volume":"16","author":"Roperch","year":"2016","journal-title":"BMC cancer"},{"issue":"4","key":"10.1016\/j.urolonc.2024.12.263_bib0045","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.euo.2018.06.011","article-title":"Performance of the bladder EpiCheck methylation test for patients under surveillance for non-muscle-invasive bladder cancer: results of a multicenter, prospective, blinded clinical trial","volume":"1","author":"Witjes","year":"2018","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2024.12.263_bib0046","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00216-008-2287-2","article-title":"Lateral flow (immuno) assay: its strengths, weaknesses, opportunities and threats. A literature survey","volume":"393","author":"Posthuma-Trumpie","year":"2009","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.urolonc.2024.12.263_bib0047","doi-asserted-by":"crossref","first-page":"5083","DOI":"10.1021\/acsomega.8b03593","article-title":"Signal-Enhanced lateral flow immunoassay with dual gold nanoparticle conjugates for the detection of hepatitis B surface antigen","volume":"4","author":"Shen","year":"2019","journal-title":"ACS Omega"},{"key":"10.1016\/j.urolonc.2024.12.263_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2020.112015","article-title":"Recent advances in high-sensitivity detection methods for paper-based lateral-flow assay","volume":"152","author":"Nguyen","year":"2020","journal-title":"Biosens Bioelectron"},{"issue":"1","key":"10.1016\/j.urolonc.2024.12.263_bib0049","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.bios.2012.06.049","article-title":"Enhanced lateral flow immunoassay using gold nanoparticles loaded with enzymes","volume":"40","author":"Parolo","year":"2013","journal-title":"Biosens Bioelectron"},{"issue":"8","key":"10.1016\/j.urolonc.2024.12.263_bib0050","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2116\/analsci.29.799","article-title":"Lateral flow immunoassay with the signal enhanced by gold nanoparticle aggregates based on polyamidoamine dendrimer","volume":"29","author":"Shen","year":"2013","journal-title":"Anal Sci"},{"key":"10.1016\/j.urolonc.2024.12.263_bib0051","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.talanta.2016.02.017","article-title":"Improved sensitivity of lateral flow assay using paper-based sample concentration technique","volume":"152","author":"Tang","year":"2016","journal-title":"Talanta"},{"issue":"11","key":"10.1016\/j.urolonc.2024.12.263_bib0052","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00604-021-05037-z","article-title":"Recent advances in sensitivity enhancement for lateral flow assay","volume":"188","author":"Deng","year":"2021","journal-title":"Mikrochim Acta"},{"issue":"2","key":"10.1016\/j.urolonc.2024.12.263_bib0053","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.juro.2013.08.049","article-title":"Bladder cancer in Spain 2011: population based study","volume":"191","author":"Minana","year":"2014","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2024.12.263_bib0054","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/21681805.2017.1295101","article-title":"Clinical relevance of narrow-band imaging in flexible cystoscopy: the DaBlaCa-7 study","volume":"51","author":"Drejer","year":"2017","journal-title":"Scand J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.12.263_bib0055","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.euf.2023.08.002","article-title":"The diagnostic accuracy of cystoscopy for detecting bladder cancer in adults presenting with haematuria: A systematic review from the European Association of Urology Guidelines Office","volume":"10","author":"Devlies","year":"2024","journal-title":"Eur Urol Focus"},{"issue":"1","key":"10.1016\/j.urolonc.2024.12.263_bib0056","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21681805.2018.1555187","article-title":"Progress towards a Nordic standard for the investigation of hematuria: 2019","volume":"53","author":"Malmstrom","year":"2019","journal-title":"Scand J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2024.12.263_bib0057","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1067\/mda.2003.9","article-title":"The optimal use of diagnostic testing in women with acute uncomplicated cystitis","volume":"49","author":"Bent","year":"2003","journal-title":"Dis Mon"},{"issue":"9","key":"10.1016\/j.urolonc.2024.12.263_bib0058","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1001\/jama.1989.03430090076037","article-title":"Dipstick urinalysis screening of asymptomatic adults for urinary tract disorders. I. Hematuria and proteinuria","volume":"262","author":"Woolhandler","year":"1989","journal-title":"Jama"},{"issue":"8","key":"10.1016\/j.urolonc.2024.12.263_bib0059","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1515\/cclm-2023-0260","article-title":"Pitfalls in the diagnosis of hematuria","volume":"61","author":"Delanghe","year":"2023","journal-title":"Clin Chem Lab Med"},{"issue":"23","key":"10.1016\/j.urolonc.2024.12.263_bib0060","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMcp012694","article-title":"Clinical practice. Microscopic hematuria","volume":"348","author":"Cohen","year":"2003","journal-title":"New Eng J Med"},{"issue":"1","key":"10.1016\/j.urolonc.2024.12.263_bib0061","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3233\/BLC-160068","article-title":"Dipstick urinalysis as a test for microhematuria and occult bladder cancer","volume":"3","author":"Matulewicz","year":"2017","journal-title":"Bladder Cancer"},{"issue":"1","key":"10.1016\/j.urolonc.2024.12.263_bib0062","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1186\/s13104-016-2240-y","article-title":"Evidence of dipstick superiority over urine microscopy analysis for detection of hematuria","volume":"9","author":"Bataille","year":"2016","journal-title":"BMC Res Notes"},{"issue":"2 Pt 1","key":"10.1016\/j.urolonc.2024.12.263_bib0063","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0022-5347(17)36575-8","article-title":"Home screening for hematuria: results of a multiclinic study","volume":"148","author":"Messing","year":"1992","journal-title":"J Urol"},{"issue":"7393","key":"10.1016\/j.urolonc.2024.12.263_bib0064","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/bmj.326.7393.813","article-title":"Time to abandon testing for microscopic haematuria in adults?","volume":"326","author":"Malmstrom","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.urolonc.2024.12.263_bib0065","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2340\/sju.v58.11142","article-title":"Abandoning testing for asymptomatic microscopic haematuria in Sweden - a long-term follow-up","volume":"58","author":"Malmstrom","year":"2023","journal-title":"Scand J Urol"},{"key":"10.1016\/j.urolonc.2024.12.263_bib0066","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jprot.2013.04.024","article-title":"Identification of potential bladder cancer markers in urine by abundant-protein depletion coupled with quantitative proteomics","volume":"85","author":"Chen","year":"2013","journal-title":"Journal of proteomics"},{"issue":"6","key":"10.1016\/j.urolonc.2024.12.263_bib0067","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/bjc.2015.21","article-title":"Protein shedding in urothelial bladder cancer: prognostic implications of soluble urinary EGFR and EpCAM","volume":"112","author":"Bryan","year":"2015","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.urolonc.2024.12.263_bib0068","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1373\/clinchem.2004.042192","article-title":"Complement factor H as a marker for detection of bladder cancer","volume":"51","author":"Cheng","year":"2005","journal-title":"Clin Chem"},{"issue":"12","key":"10.1016\/j.urolonc.2024.12.263_bib0069","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2023.06.013","article-title":"BTA stat(R), NMP22(R) BladderChek(R), UBC(R) rapid Test, and CancerCheck(R) UBC(R) rapid VISUAL as urinary marker for bladder cancer: final results of a German multicenter study","volume":"41","author":"Ecke","year":"2023","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.12.263_bib0070","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12967-021-02796-4","article-title":"Diagnostic performance of Oncuria, a urinalysis test for bladder cancer","volume":"19","author":"Hirasawa","year":"2021","journal-title":"J Transl Med"},{"issue":"8","key":"10.1016\/j.urolonc.2024.12.263_bib0071","doi-asserted-by":"crossref","first-page":"e42452","DOI":"10.1371\/journal.pone.0042452","article-title":"Detection of bladder cancer using proteomic profiling of urine sediments","volume":"7","author":"Majewski","year":"2012","journal-title":"PloS one"},{"issue":"6","key":"10.1016\/j.urolonc.2024.12.263_bib0072","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/j.juro.2013.06.011","article-title":"Multiplex protein signature for the detection of bladder cancer in voided urine samples","volume":"190","author":"Rosser","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2024.12.263_bib0073","doi-asserted-by":"crossref","first-page":"S400","DOI":"10.1016\/S0302-2838(24)00367-1","article-title":"Effect of hematuria on the performance of BTA stat\u00ae, UBC\u00ae rapid test and NMP22\u00ae as urine-based biomarker for bladder cancer detection","volume":"85","author":"Weiss","year":"2024","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2024.12.263_bib0074","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/21681805.2017.1313309","article-title":"Evaluation of the diagnostic accuracy of UBC(R) Rapid in bladder cancer: a Swedish multicentre study","volume":"51","author":"Styrke","year":"2017","journal-title":"Scandinav J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2024.12.263_bib0075","doi-asserted-by":"crossref","first-page":"e37797","DOI":"10.1371\/journal.pone.0037797","article-title":"CCL18 in a multiplex urine-based assay for the detection of bladder cancer","volume":"7","author":"Urquidi","year":"2012","journal-title":"PloS one"},{"issue":"5","key":"10.1016\/j.urolonc.2024.12.263_bib0076","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.bbapap.2013.12.007","article-title":"Biomarker research with prospective study designs for the early detection of cancer","volume":"1844","author":"Pesch","year":"2014","journal-title":"Biochimica et biophysica acta"},{"issue":"13","key":"10.1016\/j.urolonc.2024.12.263_bib0077","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1177\/1352458513488232","article-title":"Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis","volume":"19","author":"Teunissen","year":"2013","journal-title":"Mult Scler"},{"issue":"4","key":"10.1016\/j.urolonc.2024.12.263_bib0078","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1158\/1055-9965.EPI-10-0069","article-title":"Urine collection and processing for protein biomarker discovery and quantification","volume":"19","author":"Thomas","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"10.1016\/j.urolonc.2024.12.263_bib0079","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12882-021-02377-z","article-title":"Cytomegalovirus in urinary sediment in patients with acute kidney injury","volume":"22","author":"Pajenda","year":"2021","journal-title":"BMC Nephrol"},{"issue":"5","key":"10.1016\/j.urolonc.2024.12.263_bib0080","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.urology.2013.05.056","article-title":"Overestimation of nuclear matrix protein 22 in concentrated urine","volume":"82","author":"Joung","year":"2013","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.urolonc.2024.12.263_bib0081","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317691183","article-title":"The impact of advanced proteomics in the search for markers and therapeutic targets of bladder cancer","volume":"39","author":"Zhang","year":"2017","journal-title":"Tumour Biol"},{"issue":"6","key":"10.1016\/j.urolonc.2024.12.263_bib0082","first-page":"1104","article-title":"Urine protein biomarkers for the detection, surveillance, and treatment response prediction of bladder cancer","volume":"9","author":"Chakraborty","year":"2019","journal-title":"Am J Cancer Res"},{"issue":"5","key":"10.1016\/j.urolonc.2024.12.263_bib0083","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/14737159.2018.1469979","article-title":"Molecular markers in disease detection and follow-up of patients with non-muscle invasive bladder cancer","volume":"18","author":"Maas","year":"2018","journal-title":"Expert Rev Mol Diagn"},{"issue":"7","key":"10.1016\/j.urolonc.2024.12.263_bib0084","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1586\/14737140.8.7.1111","article-title":"Bladder tumor markers: from hematuria to molecular diagnostics\u2013where do we stand?","volume":"8","author":"Shirodkar","year":"2008","journal-title":"Expert Rev Anticancer Ther"},{"issue":"11","key":"10.1016\/j.urolonc.2024.12.263_bib0085","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.21037\/tcr-20-1824","article-title":"The diagnostic and prognostic value of nuclear matrix protein 22 in bladder cancer","volume":"9","author":"Tang","year":"2020","journal-title":"Transl Cancer Res"},{"issue":"4","key":"10.1016\/j.urolonc.2024.12.263_bib0086","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1054\/bjoc.2001.1938","article-title":"Prognostic utility of human complement factor H related protein test (the BTA stat Test)","volume":"85","author":"Raitanen","year":"2001","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.urolonc.2024.12.263_bib0087","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.clgc.2012.06.003","article-title":"Discovery of potential bladder cancer biomarkers by comparative urine proteomics and analysis","volume":"11","author":"Lei","year":"2013","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"10.1016\/j.urolonc.2024.12.263_bib0088","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.bbrc.2014.03.053","article-title":"Discovery of Apo-A1 as a potential bladder cancer biomarker by urine proteomics and analysis","volume":"446","author":"Li","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.urolonc.2024.12.263_bib0089","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1477-5956-9-21","article-title":"Identification of Apo-A1 as a biomarker for early diagnosis of bladder transitional cell carcinoma","volume":"9","author":"Li","year":"2011","journal-title":"Proteome Sci"},{"issue":"10","key":"10.1016\/j.urolonc.2024.12.263_bib0090","doi-asserted-by":"crossref","first-page":"e47469","DOI":"10.1371\/journal.pone.0047469","article-title":"A multi-analyte assay for the non-invasive detection of bladder cancer","volume":"7","author":"Goodison","year":"2012","journal-title":"PloS One"},{"issue":"15","key":"10.1016\/j.urolonc.2024.12.263_bib0091","doi-asserted-by":"crossref","first-page":"13539","DOI":"10.18632\/oncotarget.3841","article-title":"Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma","volume":"6","author":"Kumar","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.urolonc.2024.12.263_bib0092","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s10020-018-0047-0","article-title":"Serum amyloid A - a review","volume":"24","author":"Sack","year":"2018","journal-title":"Mol Med"},{"key":"10.1016\/j.urolonc.2024.12.263_bib0093","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1135490","article-title":"The human factor H protein family - an update","volume":"15","author":"Sandor","year":"2024","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.urolonc.2024.12.263_bib0094","doi-asserted-by":"crossref","DOI":"10.3390\/nano11092384","article-title":"Detection of circulating serum protein biomarkers of non-muscle invasive bladder cancer after protein corona-silver nanoparticles analysis by SWATH-MS","volume":"11","author":"Gomez","year":"2021","journal-title":"Nanomaterials (Basel)"},{"issue":"1","key":"10.1016\/j.urolonc.2024.12.263_bib0095","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/(SICI)1097-0339(199907)21:1<27::AID-DC8>3.0.CO;2-8","article-title":"Utility of the BTA stat test kit for bladder cancer screening","volume":"21","author":"Nasuti","year":"1999","journal-title":"Diagn Cytopathol"},{"issue":"12","key":"10.1016\/j.urolonc.2024.12.263_bib0096","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1038\/sj.bjc.6605979","article-title":"Cancer and renal insufficiency results of the BIRMA study","volume":"103","author":"Janus","year":"2010","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.urolonc.2024.12.263_bib0097","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.semnephrol.2010.09.003","article-title":"Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA study group","volume":"30","author":"Launay-Vacher","year":"2010","journal-title":"Semin Nephrol"},{"issue":"Suppl 1","key":"10.1016\/j.urolonc.2024.12.263_bib0098","first-page":"S14","article-title":"Standards of medical care in diabetes\u20132014","volume":"37","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.urolonc.2024.12.263_bib0099","first-page":"S76","article-title":"Proteinuria and hypertension","volume":"47","author":"Ritz","year":"1994","journal-title":"Kidney Int Suppl"},{"issue":"1","key":"10.1016\/j.urolonc.2024.12.263_bib0100","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/cncy.22767","article-title":"Urinary IL-6 and IL-8 as predictive markers in bladder urothelial carcinoma: A pilot study","volume":"132","author":"VandenBussche","year":"2024","journal-title":"Cancer Cytopathol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.12.263_bib0101","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0090-4295(99)80378-1","article-title":"Prognostic value of urokinase-type plasminogen activator in patients with superficial bladder cancer","volume":"47","author":"Hasui","year":"1996","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.urolonc.2024.12.263_bib0102","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/ijc.10426","article-title":"Expression of UPA and UPAR is associated with the clinical course of urinary bladder neoplasms","volume":"99","author":"Seddighzadeh","year":"2002","journal-title":"Int J Cancer"},{"issue":"6 Pt 1","key":"10.1016\/j.urolonc.2024.12.263_bib0103","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1097\/01.ju.0000090965.71697.37","article-title":"The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer","volume":"170","author":"Shariat","year":"2003","journal-title":"J Urol"},{"issue":"12","key":"10.1016\/j.urolonc.2024.12.263_bib0104","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1002\/cncr.10989","article-title":"Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma","volume":"95","author":"Casella","year":"2002","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.urolonc.2024.12.263_bib0105","doi-asserted-by":"crossref","first-page":"e22275","DOI":"10.1002\/jbt.22275","article-title":"MMP-2 and MMP-9 as prognostic markers for the early detection of urinary bladder cancer","volume":"33","author":"Fouad","year":"2019","journal-title":"J Biochem Mol Toxicol"},{"issue":"12","key":"10.1016\/j.urolonc.2024.12.263_bib0106","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.3390\/ijms19123841","article-title":"UBC(R) rapid test-A urinary point-of-care (POC) assay for diagnosis of bladder cancer with a focus on non-muscle invasive high-grade tumors: results of a multicenter-study","volume":"19","author":"Ecke","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.urolonc.2024.12.263_bib0107","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/172460089400900201","article-title":"Cytokeratins in the histological diagnosis of malignant tumors","volume":"9","author":"Moll","year":"1994","journal-title":"Int J Biol Markers"},{"issue":"11","key":"10.1016\/j.urolonc.2024.12.263_bib0108","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1158\/1078-0432.CCR-07-0009","article-title":"Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy","volume":"13","author":"H\u00e4gg Olofsson","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.urolonc.2024.12.263_bib0109","first-page":"1279","article-title":"Role of NMP22 bladder check test in early detection of bladder cancer with recurrence","volume":"11","author":"Kundal","year":"2010","journal-title":"Asian Pac J Cancer Prev"},{"issue":"2-3","key":"10.1016\/j.urolonc.2024.12.263_bib0110","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1615\/CritRevEukarGeneExpr.v6.i2-3.50","article-title":"Utilization of nuclear matrix proteins for cancer diagnosis","volume":"6","author":"Keesee","year":"1996","journal-title":"Critic Rev Eukaryot Gene Express"},{"issue":"4","key":"10.1016\/j.urolonc.2024.12.263_bib0111","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S0022-5347(05)66428-2","article-title":"Current bladder tumor tests: does their projected utility fulfill clinical necessity?","volume":"165","author":"Lokeshwar","year":"2001","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2024.12.263_bib0112","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/sj.cdd.4401010","article-title":"Proteome analysis of nuclear matrix proteins during apoptotic chromatin condensation","volume":"9","author":"Gerner","year":"2002","journal-title":"Cell Death Differen"},{"issue":"2","key":"10.1016\/j.urolonc.2024.12.263_bib0113","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3233\/CBM-200316","article-title":"MCM5 urine expression (ADXBLADDER) is a reliable biomarker of high-risk non- muscle-invasive bladder cancer recurrence: A prospective matched case-control study","volume":"30","author":"Bialek","year":"2021","journal-title":"Cancer Biomark"},{"issue":"6","key":"10.1016\/j.urolonc.2024.12.263_bib0114","doi-asserted-by":"crossref","DOI":"10.1016\/j.acthis.2023.152072","article-title":"MCM5 is an oncogene of colon adenocarcinoma and promotes progression through cell cycle control","volume":"125","author":"Mao","year":"2023","journal-title":"Acta Histochem"},{"issue":"3","key":"10.1016\/j.urolonc.2024.12.263_bib0115","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1470-2045(06)70584-8","article-title":"Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis","volume":"7","author":"Theodorescu","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2024.12.263_bib0116","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/4591910","article-title":"Multiplatform biomarker discovery for bladder cancer recurrence diagnosis","volume":"2016","author":"De Paoli","year":"2016","journal-title":"Dis Markers"},{"issue":"1","key":"10.1016\/j.urolonc.2024.12.263_bib0117","article-title":"Multiplex Lateral flow immunoassay: an overview of strategies towards high-throughput point-of-need testing","volume":"9","author":"Anfossi","year":"2018","journal-title":"Biosensors (Basel)"},{"issue":"15","key":"10.1016\/j.urolonc.2024.12.263_bib0118","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1039\/C9LC00104B","article-title":"Sensitivity enhancement in lateral flow assays: a systems perspective","volume":"19","author":"Bishop","year":"2019","journal-title":"Lab Chip"},{"issue":"35","key":"10.1016\/j.urolonc.2024.12.263_bib0119","doi-asserted-by":"crossref","first-page":"37500","DOI":"10.18632\/oncotarget.6061","article-title":"Urine BLCA-4 exerts potential role in detecting patients with bladder cancers: a pooled analysis of individual studies","volume":"6","author":"Cai","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2024.12.263_bib0120","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/5609395","article-title":"Bladder cancer-specific nuclear matrix proteins-4 may Be a potential biomarker for non-muscle-invasive Bladder cancer detection","volume":"2018","author":"Wang","year":"2018","journal-title":"Dis Markers"},{"issue":"1","key":"10.1016\/j.urolonc.2024.12.263_bib0121","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.euo.2019.06.006","article-title":"A novel, non-invasive test enabling bladder cancer detection in urine sediment of patients presenting with haematuria-A prospective multicentre performance evaluation of ADXBLADDER","volume":"3","author":"Dudderidge","year":"2020","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2024.12.263_bib0122","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.urolonc.2013.09.024","article-title":"Evaluation of a new quantitative point-of-care test platform for urine-based detection of bladder cancer","volume":"32","author":"Ritter","year":"2014","journal-title":"Urol Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924010433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924010433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T14:42:43Z","timestamp":1748443363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924010433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":122,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1078143924010433"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.12.263","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of point-of-care tests for urinary bladder cancer \u2013 an historic review and view to future prospectives","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.12.263","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}